13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

21 trials found

diseases per page:

Showing 1 to 10 of 21 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05482542 (ClinicalTrials.gov)	January 1, 2023	12/7/2022	Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosi ...	Optimal Conditioning Regimen Protocol for Autologous Hematopoietic Stem Cell Transplantation of Rela ...	Multiple Sclerosis, Relapsing-Remitting	Other: Autologous hematopoietic stem cell transplantation;Drug: Cyclophosphamide /ATG;Drug: Cyclophos ...	Scripps Health	NULL	Recruiting	18 Years	58 Years	All	200	N/A	United States
2	NCT04561557 (ClinicalTrials.gov)	September 22, 2020	10/9/2020	Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammat ...	An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment o ...	Autoimmune Diseases;Autoimmune Diseases of the Nervous System;Neuromyelitis Optica Spectrum Disorder ...	Biological: CT103A cells;Drug: Cyclophosphamide and fludarabine	Tongji Hospital	Nanjing IASO Biotherapeutics Co.,Ltd	Recruiting	18 Years	75 Years	All	18	Early Phase 1	China
3	EUCTR2019-001549-42-GB (EUCTR)	27/03/2020	03/02/2020	Stem cell transplantation versus disease modifying therapy (alemtuzumab or ocrelizumab) for patients ...	A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic ste ...	Highly active relapsing remitting multiple sclerosis MedDRA version: 20.1;Level: PT;Classification c ...	Product Name: Cyclophosphamide INN or Proposed INN: Cyclophosphamide monohydrate INN or Proposed INN: C ...	Sheffield Teaching Hospitals	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	198	Phase 3	United Kingdom
4	NCT03829566 (ClinicalTrials.gov)	November 2019	1/2/2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;B ...	Northwestern University	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
5	EUCTR2017-001362-25-NL (EUCTR)	30/09/2019	10/09/2019	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocre ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Denmark;Netherlands
6	EUCTR2017-001362-25-DK (EUCTR)	27/06/2018	21/03/2018	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocre ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Sendoxane Product Name: Cyclophosphamide Trade Name: Thymoglobuline ® Product Name: Thymoglo ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Denmark;Netherlands
7	EUCTR2017-001362-25-SE (EUCTR)	02/05/2018	17/10/2017	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocre ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Sendoxane Product Name: Cyclophosphamide Trade Name: Thymoglobuline ® Product Name: Thymoglo ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Denmark;Netherlands;Sweden
8	NCT03477500 (ClinicalTrials.gov)	March 21, 2018	13/2/2018	RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or O ...	Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocre ...	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab;Drug: Cladribine Pill;Drug: Ocrelizumab	Haukeland University Hospital	NULL	Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
9	NCT03342638 (ClinicalTrials.gov)	November 8, 2017	9/11/2017	Maximizing Outcome of Multiple Sclerosis Transplantation	Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial	Multiple Sclerosis, Relapsing-Remitting	Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg; ...	Northwestern University	NULL	Terminated	18 Years	58 Years	All	66	Phase 3	United States
10	NCT02529839 (ClinicalTrials.gov)	October 2015	10/6/2015	Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone ...	Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone ...	Multiple Sclerosis	Procedure: Autologous bone marrow transplantation;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Ale ...	Hadassah Medical Organization	NULL	Not yet recruiting	18 Years	65 Years	Both	20	N/A	NULL

First Previous1 2 3Next Last